Literature DB >> 20981126

Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia?

Frederick R Appelbaum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20981126     DOI： 10.1038/nrclinonc.2010.169

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

Review 1.  MGMT: its role in cancer aetiology and cancer therapeutics.

Authors:  Stanton L Gerson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

2.  The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.

Authors:  Francis J Giles; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Deborah Thomas; William Wierda; Alessandra Ferrajoli; Steven Kornblau; Sherry Pierce; Maher Albitar; Jorge Cortes; Hagop Kantarjian
Journal:  Br J Haematol       Date:  2007-02       Impact factor: 6.998

3.  Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.

Authors:  Arnaud Pigneux; Jean-Luc Harousseau; Francis Witz; Mathieu Sauvezie; Marie-Christine Bene; Isabelle Luquet; Mathilde Hunault-Berger; Christian Recher; Bruno Lioure; Chantal Himberlin; Martine Escoffre-Barbe; Christian Berthou; Severine Lissandre; Nathalie Fegueux; Jean-Yves Cahn; Eric Jourdan; François Dreyfus; Josy Reiffers; Noël Milpied; Norbert Ifrah
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

4.  Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.

Authors:  Gary J Schiller; Susan M O'Brien; Arnaud Pigneux; Daniel J Deangelo; Norbert Vey; Jonathan Kell; Scott Solomon; Robert K Stuart; Verena Karsten; Ann L Cahill; Maher X Albitar; Francis J Giles
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

5.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

6.  Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.

Authors:  David Rizzieri; Samantha LoRusso; William Tse; Khuda Khan; Anjali Advani; Joseph Moore; Verena Karsten; Ann Cahill; Stanton L Gerson
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-06

7.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

8.  Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.

Authors:  S B Kahn; C B Begg; J J Mazza; J M Bennett; H Bonner; J H Glick
Journal:  J Clin Oncol       Date:  1984-08       Impact factor: 44.544

9.  Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.

Authors:  Arnaud Pigneux; Virginie Perreau; Eric Jourdan; Norbert Vey; Nicole Dastugue; Françoise Huguet; Jean-Jacques Sotto; L Rachid Salmi; Norbert Ifrah; Josy Reiffers
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

10.  Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Michael B Maris; Frédéric Baron; David G Maloney; Bart L Scott; H Joachim Deeg; Frederick R Appelbaum; Rainer Storb
Journal:  J Clin Oncol       Date:  2007-08-27       Impact factor: 44.544
  10 in total
  1 in total

1.  Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience.

Authors:  Sarah Bertoli; Suzanne Tavitian; Pierre Bories; Isabelle Luquet; Eric Delabesse; Thibault Comont; Audrey Sarry; Françoise Huguet; Emilie Bérard; Christian Récher
Journal:  Cancer Med       Date:  2019-06-07       Impact factor: 4.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.